Recently, Dow component Johnson & Johnson (NYSE: JNJ) reported its earning for its third quarter ending on September 20th. The company beat Wall Street’s earning projections. Its revenue slipped by 5.3% versus its third quarter of 2009. After the announcement, its shares fell and closed down on the day by more than 2%.
While the decline in JNJ’s share price on a revenue miss was expected, it does not tell the whole story. Johnson & Johnson has long been considered to be one of the pillars of the Dow 30 Industrial composite and the United States’ best-managed health-care company. Up until 2009, Johnson & Johnson had increased its annualized revenue for the past 35 consecutive years. That has all changed because the company’s revenue has declined for the third straight quarter, and revenue for its calendar year ending Dec 31 is expected to decline. To discover what this means for the Dow overall and to read Michael Markowski’s full article, sign up for a free one-year subscription to EQUITIES Magazine. To access the current issue of EQUITIES Magazine and more, click here.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
